Britannia Life Sciences Inc.
BLAB
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -- | -97.80K | -875.80K | -539.40K | -- |
| Total Depreciation and Amortization | -- | 39.50K | 38.80K | 37.30K | -- |
| Total Amortization of Deferred Charges | -- | 33.90K | 26.40K | 17.60K | -- |
| Total Other Non-Cash Items | -- | 117.70K | 705.80K | 525.40K | -- |
| Change in Net Operating Assets | -- | 401.30K | 170.80K | -31.30K | -- |
| Cash from Operations | -- | 494.60K | 66.00K | 9.50K | 236.70K |
| Capital Expenditure | -- | -9.00K | -1.90K | -1.70K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -64.70K | -66.80K | -61.30K | -- |
| Cash from Investing | -- | -73.70K | -68.70K | -63.00K | -131.30K |
| Total Debt Issued | -- | 0.00 | 771.50K | -- | -- |
| Total Debt Repaid | -- | -574.50K | -578.40K | -520.00K | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -410.40K | 141.60K | -380.00K | -416.40K |
| Foreign Exchange rate Adjustments | -- | -1.10K | 33.30K | 9.40K | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | 9.40K | 172.20K | -424.00K | -291.90K |